Analysis on the current status of targeted drug delivery to tumors
about
Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systemsA liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or densityCyanine 5.5 conjugated nanobubbles as a tumor selective contrast agent for dual ultrasound-fluorescence imaging in a mouse modelNANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?Heterogeneous Uptake of Nanoparticles in Mouse Models of Pediatric High-Risk NeuroblastomaPolymeric Nanostructures for Imaging and TherapyOf drug administration, war and oïkos: mediating cancer with nanomedicines.Phage protein-targeted cancer nanomedicines.Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingCancer nanomedicines: oversold or underappreciated?Gadolinium Complex of (125)I/(127)I-RGD-DOTA Conjugate as a Tumor-Targeting SPECT/MR Bimodal Imaging Probe.Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imagingHyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes.Selective recognition of anionic cell membranes using targeted liposomes coated with zinc(ii)-bis(dipicolylamine) affinity units.Controlled drug delivery systems: past forward and future back.The nano-plasma interface: Implications of the protein corona.Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeuticsThe effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulationApplication of chitosan-based nanocarriers in tumor-targeted drug delivery.NANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip.Smart Nanoparticles for Drug Delivery: Boundaries and OpportunitiesTherapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids.Curcumin-encapsulated polymeric micelles suppress the development of colon cancer in vitro and in vivoComplete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π-Π Stacking Stabilized Polymeric Micelles.Different patterns of nuclear and mitochondrial penetration by the G3 PAMAM dendrimer and its biotin-pyridoxal bioconjugate BC-PAMAM in normal and cancer cells in vitroSynthesis and in vivo magnetic resonance imaging evaluation of biocompatible branched copolymer nanocontrast agentsBiological rationale for the design of polymeric anti-cancer nanomedicines.Intracellular GSH-activated galactoside photosensitizers for targeted photodynamic therapy and chemotherapy.Multistage vector (MSV) therapeutics.Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer.Microdistribution of MC1R-targeted polyplexes in murine melanoma tumor tissue.Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorptionA conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancerFacing the truth about nanotechnology in drug delivery.Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities.
P2860
Q26778701-71EA2BFC-6639-45AA-BCFA-050B367ABA84Q27025606-CBD2DAD8-D93F-4DF6-ACD4-7948A5D8A41DQ27308658-617A54E3-EE7C-4754-AEE7-2DCB771B0F62Q27325573-DE9CB8F3-AFE1-45CA-BFA7-A2BFECD8BA4BQ28078448-3ABFC84D-A1EB-41FF-8736-2A5E2838E262Q28553602-68D5F032-DA5A-40CE-81A7-C5AD8C2F52E0Q30372383-0B3BFF58-575B-4442-8AC4-007E67905C67Q30380301-541E8D85-5ED6-4EC0-9BE4-5A21AC756F6CQ30403553-A2011ED7-7E72-467C-AE21-AF622C6FA770Q30456053-5F8F0D52-E6E3-4052-89A5-B1507D848C87Q33602272-2AE03901-122B-4FF8-8A0E-19B472BC8299Q33636069-2BB229C3-71BD-4A18-89BC-435F43CA868FQ33651804-A8E5FFA9-7817-45A4-AC9A-2D759DF6EB14Q33811463-1CF72F90-8078-4902-BF1F-9B26D9682156Q34026778-2BF235C3-F837-4AC2-BE95-1E1B738A482EQ34079613-FDEB646F-D31A-4A26-AEC0-2947FDE4EE4DQ34122883-78E43FB3-E820-4614-98BC-C752C0BF8DF1Q34205366-DC417347-6A55-46B8-9FEC-68DE962BEE79Q34270352-C8847CBA-C9C1-4206-8618-19AF2A293B2BQ34447152-9DC98ABC-37B7-45EB-83A8-254604F720FFQ34534023-3283F7FA-F576-4669-BF4B-B84B3276CD82Q34613544-DBAD0390-CF37-4A2A-B9B4-93BABC7ABC72Q35067230-F0D03019-4F1D-4E87-9066-F0485D06A3D5Q35176800-1317C118-D468-4DAA-841E-0DD05F29669DQ35410974-85BDE67B-196F-47A6-AAC0-B47E1A03D9AEQ35616700-64634813-7B1B-4C17-9314-DCBC4E7BDD5DQ35911710-8C8A22CD-E8EA-4EBF-8B2F-1CE4DD315DD9Q36052346-15C244AD-AA26-4F64-8286-DE2048DCA7CFQ36093308-94C6C8A6-E239-48D4-9391-79C43EEDB48EQ36160333-D411C6B0-C926-47A8-8127-3F4F759DBE61Q36220307-E0F0F7ED-0090-46C5-8DE5-4CB5616D7B35Q36307634-679AF7C0-C09C-4E3A-931B-66133D1697F1Q36414417-45A0D96B-8A8D-4B54-8BDA-0BE93945A8B0Q36867763-75A35867-516D-4A94-B158-0A29044E87F5Q36971463-511DEDAF-7437-427A-9868-8C45C3F9276CQ37230140-D94DCC1E-6980-48E9-984D-117CDC7A7D82Q37256120-195DEE79-76F1-4CB9-963A-43F62B8A5372Q37274382-DF49925F-ADAF-4FA0-B752-B9138ACA71EAQ37555555-6EE7AA8C-F466-4BAD-95F5-0DFE3884815CQ37626377-B1FC79AF-3964-4711-A2FA-D539AD60D70C
P2860
Analysis on the current status of targeted drug delivery to tumors
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Analysis on the current status of targeted drug delivery to tumors
@en
type
label
Analysis on the current status of targeted drug delivery to tumors
@en
prefLabel
Analysis on the current status of targeted drug delivery to tumors
@en
P2093
P2860
P1476
Analysis on the current status of targeted drug delivery to tumors
@en
P2093
Bumsoo Han
Il Keun Kwon
Kinam Park
Sang Cheon Lee
P2860
P304
P356
10.1016/J.JCONREL.2012.07.010
P407
P577
2012-07-16T00:00:00Z